You are viewing an incomplete version of our website. Please click to reload the website as full version.

DOK2 (C-Term) antibody

Details for Product No. ABIN359960, Supplier: Log in to see
Antigen
  • DokR
  • Frip
  • Dok-2
  • p56DOK
  • p56dok-2
Epitope
C-Term
41
26
13
13
13
5
3
2
2
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
160
64
34
2
2
1
Host
Rabbit
146
14
Clonality
Polyclonal
Conjugate
Un-conjugated
6
6
6
4
4
4
4
4
4
4
4
4
2
2
2
Application
Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
105
59
44
36
34
23
8
3
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human DOK2.
Isotype Ig
Specificity This antibody reacts to DOK2.
Purification Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
Alternative Name DOK2 / p56 Dok2
Background Docking proteins interact with receptor tyrosine kinases and mediate particular biological responses using signal transduction. Dok-2 acts as a multiple docking protein downstream of receptor or non-receptor tyrosine kinases. By this mechanism it acts to negatively regulate signal transduction and cell proliferation controlled by cytokines in a feedback loop. Dok-2 is highly expressed in cells and tissues of hematopoietic origin as well as in lung. Expression of bcr/abl induces additional tyrosine phosphorylation of the Dok1 and Dok2 proteins and their association with Ras-GAP. Thus, it is suspected that DOK association regulates GAP activity toward Ras and that the Dok proteins serve as mediators of bcr-abl signaling. The role of Dok proteins in bcr-abl regulation may also be implicated in chronic myelogenous leukemia (CML), which is characterized by a Philadelphia chromosome translocation t(9,22). Such a mutation would result in a p210-bcr/abl chimeric protein-tyrosine kinase which has been found in many CML cases.Synonyms: Docking protein 2, Downstream of tyrosine kinase 2, p56(dok-2), p56Dok-2
Gene ID 9046, 9606
UniProt O60496
Application Notes ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Supplier Images
 image for anti-DOK2 (C-Term) antibody (ABIN359960) anti-DOK2 (C-Term) antibody
 image for anti-DOK2 (C-Term) antibody (ABIN359960) anti-DOK2 (C-Term) antibody (Image 2)
Background publications Salomon, Ficarro, Brill et al.: "Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, Issue 2, pp. 443-8, 2003 (PubMed).

Di Cristofano, Carpino, Dunant et al.: "Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins." in: The Journal of biological chemistry, Vol. 273, Issue 9, pp. 4827-30, 1998 (PubMed).